Experimental therapeutics for refractory obsessive-compulsive disorder: Translational approaches and new somatic developments

Mount Sinai Journal of Medicine

Volumn 75, Issue 3, 2008, Pages 174-203

  Berlin, Heather A ^a   Hamilton, Holly ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Caudate nucleus; Cingulate gyrus; Deep brain stimulation; Internal capsule; Neurosurgery; Obsessive compulsive disorder; Prefrontal cortex; Serotonin reuptake inhibitors; Therapeutics; Transcranial magnetic stimulation

Indexed keywords

BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DIAZEPAM; DOPAMINE TRANSPORTER; EXCITATORY AMINO ACID TRANSPORTER 3; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PAROXETINE; PLACEBO; POSTSYNAPTIC DENSITY PROTEIN 95; QUETIAPINE; QUINPIROLE; RILUZOLE; RISPERIDONE; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG;

ANIMAL BEHAVIOR; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE THERAPY; COMPULSION; DOPAMINERGIC SYSTEM; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GROOMING; HERITABILITY; HUMAN; MONOTHERAPY; NEUROBIOLOGY; NEUROIMAGING; NEUROMODULATION; NEUROSURGERY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PATHOPHYSIOLOGY; POLYDIPSIA; PREFRONTAL CORTEX; PSYCHOLOGICAL ASPECT; RISK FACTOR; STEREOTYPY; THERMOCOAGULATION; TRANSCRANIAL MAGNETIC STIMULATION;

DEEP BRAIN STIMULATION; ELECTROCONVULSIVE THERAPY; HUMANS; MODELS, ANIMAL; MODELS, GENETIC; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE;

EID: 55549147907     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20045     Document Type: Article

References (381)

1. Hay P, Sachdev P, Cumming S, et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 1993; 87: 197-207.
2. DuPont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface 1995; 8: 102-109.
3. Steketee G. Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry 1997; 42: 919-928.
4. Stein D, Allen A, Bobes J, et al. Quality of life in obsessive compulsive disorder. CNS Spectr 2000; 5(suppl 4): 37-39.
5. Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360: 397-405.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
7. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 1999; 60(suppl 18): 27-32.
8. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094-1099.
9. Weissman MM, Bland RC, Canino GJ, et al., for the Cross National Collaborative Group. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1994; 55(suppl): 5-10.
10. Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997; 58(suppl 12): 7-10.
11. Torres AR, Prince MJ, Bebbington PE, et al. Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry 2006; 163: 1978-1985.
12. Robins IN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949-958.
13. Stein MB, Forde DR, Anderson G, et al. Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Am J Psychiatry 1997; 154: 1120-1126.
14. Skoog G, Skoog I. A 40-year. follow-up of patients with obsessive-compulsive disorder [see comments]. Arch Gen Psychiatry 1999; 56: 121-127.
15. Welkowitz LA, Struening EL, Pittman J, et al. Obsessive-compulsive disorder and comorbid anxiety problems in a national anxiety screening sample. J Anxiety Disord 2000; 14: 471-482.
16. Nestadt G, Addington A, Samuels J, et al. The identification of OCD-related subgroups based on comorbidity. Biol Psychiatry 2003; 53: 914-920.
17. Biederman J, Petty C, Faraone SV, et al. Moderating effects of major depression on patterns of comorbidity in patients with panic disorder. Psychiatry Res 2004; 126: 143-149.
18. LaSalle VH, Cromer KR, Nelson KN, et al. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depress Anxiety 2004; 19: 163-173.
19. Apter A, Horesh N, Gothelf D, et al. Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder. J Affect Disord 2003; 75: 181-189.
20. Abramowitz JS, Schwartz SA, Moore KM, et al. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. J Anxiety Disord 2003; 17: 461-478.
21. Abramowitz JS. Treatment of obsessive-compulsive disorder in patients who have comorbid major depression. J Clin Psychol 2004; 60: 1133-1141.
22. Fals-Stewart W, Angarano K. Obsessive-compulsive disorder among patients entering substance abuse treatment. Prevalence and accuracy of diagnosis. J Nerv Ment Dis 1994; 182: 715-719.
23. Abram KM, Teplin LA, McClelland GM, et al. Comorbid psychiatric disorders in youth in juvenile detention. Arch Gen Psychiatry 2003; 60: 1097-1108.
24. Bakken K, Landheim AS, Vaglum P. Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders? Alcohol Alcohol 2003; 38: 54-59.
25. Jordan J, Joyce PR, Carter FA, et al. Anxiety and psychoactive substance use disorder comorbidity in anorexia nervosa or depression. Int J Eat Disord 2003; 34: 211-219.
26. Frare F, Perugi G, Ruffolo G, et al. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features. Eur Psychiatry 2004; 19: 292-298.
27. Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164: 5-53.
28. Swedo S, Snider L. In: Nestler EJ, Charney DS, eds. Neurobiology of Mental Illness. 2nd Editions. The Neurobiology and Treatment of Obsessive-Compulsive Disorder. New York, NY: Oxford University Press; 2004; 628-638.
29. Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28: 343-347.
30. Aouizerate B, Guehl D, Cuny E, et al. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 2004; 72: 195-221.
31. Saxena S, Bota RG, Brody AL. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 2001; 6: 82-101.
32. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
33. Lawrence A, Sahakian B, Robbins TW. Cognitive functions and corticostriatal circuits: insights from Huntington's disease. Trends Cogn Sci 1998; 2: 379-388.
34. Rapoport JL, Wise SP. Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol Bull 1988; 24: 380-384.
35. Saxena S. Neuroimaging and the pathophysiology of obsessive compulsive disorder (OCD). In: Fu CHY, Senior C, Russell T, Weinberger DR, eds. Neuroimaging in Psychiatry. London, United Kingdom: Martin Dunitz; 2003.
36. Menzies L, Achard S, Chamberlain SR, et al. Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007; 130: 3223-3236.
37. Rolls ET. The functions of the orbitofrontal cortex. Brain Cogn 2004; 55: 11-29.
38. Berlin HA, Rolls ET, Kischka U. Impulsivity, time perception, emotion and reinforcement sensitivity in patients with orbitofrontal cortex lesions. Brain 2004; 127: 1108-1126.
39. Chamberlain SR, Blackwell AD, Fineberg NA, et al. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markets. Neurosci Biobehav Rev 2005; 29: 399-419.
40. Tallis F. The neuropsychology of obsessive-compulsive disorder: a review and consideration of clinical implications. Br J Clin Psychol 1997; 36(pt 1): 3-20.
41. Robinson D, Wu H, Munne RA, et al. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 393-398.
42. Scarone S, Colombo C, Livian S, et al. Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res 1992; 45: 115-121.
43. Aylward EH, Harris GJ, Hoehn-Saric R, et al. Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. Arch Gen Psychiatry 1996; 53: 577-584.
44. Jenike MA, Breiter HC, Baer L, et al. Cerebral structural abnormalities in obsessive-compulsive disorder. A quantitative morphometric magnetic resonance imaging study. Arch Gen Psychiatry 1996; 53: 625-632.
45. Rosenberg DR, Keshavan MS. A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 1998; 43: 623-640.
46. Szeszko PR, Robinson D, Alvir JM, et al. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry 1999; 56: 913-919.
47. Szeszko PR, MacMillan S, McMeniman M, et al. Brain structural abnormalities in psychotropic drug-naive pediatric patients with obsessive-compulsive disorder. Am J Psychiatry 2004; 161: 1049-1056.
48. Gilbert AR, Moore GJ, Keshavan MS, et al. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch Gen Psychiatry 2000; 57: 449-456.
49. Kim JJ, Lee MC, Kim J, et al. Grey matter abnormalities in obsessive-compulsive disorder: statistical parametric mapping of segmented magnetic resonance images. Br J Psychiatry 2001; 179: 330-334.
50. Kwon JS, Shin YW, Kim CW, et al. Similarity and disparity of obsessive-compulsive disorder and schizophrenia in MR volumetric abnormalities of the hippocampus-amygdala complex. J Neurol Neurosurg Psychiatry 2003; 74: 962-964.
51. Choi JS, Kang DH, Kim JJ, et al. Left anterior subregion of orbitofrontal cortex volume reduction and impaired organizational strategies in obsessive-compulsive disorder. J Psychiatr Res 2004; 38: 193-199.
52. Choi JS, Kim HS, Yoo SY, et al. Morphometric alterations of anterior superior temporal cortex in obsessive-compulsive disorder. Depress Anxiety 2006; 23: 290-296.
53. Kang DH, Kim JJ, Choi JS, et al. Volumetric investigation of the frontal-subcortical circuitry in patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2004; 16: 342-349.
54. Atmaca M, Yildirim H, Ozdemir H, et al. Volumetric MRI study of key brain regions implicated in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 46-52.
55. Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994; 51: 62-70.
56. McKay D, Abramowitz JS, Calamari JE, et al. A critical evaluation of obsessive-compulsive disorder subtypes: symptoms versus mechanisms. Clin Psychol Rev 2004; 24: 283-313.
57. Nordahl TE, Benkelfat C, Semple WE, et al. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989; 2: 23-28.
58. Baxter LR. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. J Clin Psychiatry 1990; 51(O:suppl) 22-25.
59. McGuire PK, Bench CJ, Frith CD, et al. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994; 164: 459-468.
60. Phillips ML, Marks IM, Senior C, et al. A differential neural response in obsessive-compulsive disorder patients with washing compared with checking symptoms to disgust. Psychol Med 2000; 30: 1037-1050.
61. Lacerda AL, Dalgalarrondo P, Caetano D, et al. Elevated thalamic and prefrontal regional cerebral blood flow in obsessive-compulsive disorder: a SPECT study. Psychiatry Res 2003; 123: 125-134.
62. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004; 61: 564-576.
63. Saxena S, Brody AL, Maidment KM, et al. Cerebral glucose metabolism in obsessive-compulsive hoarding. Am J Psychiatry 2004; 161: 1038-1048.
64. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004; 132: 69-79.
65. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin N Am 2000; 23: 563-586.
66. Rauch SL. Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders. Neurosurg Clin N Am 2003; 14: 213-223, vii-viii.
67. Saxena S, Brody AL, Schwartz JM, et al. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35: 26-37.
68. Saxena S, Brody AL, Maidment KM, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999; 21: 683-693.
69. Friedlander L, Desrocher M. Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clin Psychol Rev 2006; 26: 32-49.
70. Bullmore ET, Suckling J, Overmeyer S, et al. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 1999; 18: 32-42.
71. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000; 11: 805-821.
72. Pujol J, Soriano-Mas C, Alonso P, et al. Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry 2004; 61: 720-730.
73. Valente AA Jr, Miguel EC, Castro CC, et al. Regional gray matter abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Biol Psychiatry 2005; 58: 479-487.
74. Husted DS, Shapira NA, Goodman WK. Obsessive-compulsive disorder. In: Tarazi FI, Schetz JA, eds. Neurological and Psychiatric Disorders: From Bench to Bedside. Totowa, NJ: Humana Press; 2005; 171-188.
75. Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44: 946-951.
76. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49: 21-28.
77. Stein DJ, Van Heerden B, Wessels CJ, et al. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 1079-1099.
78. Adams KH, Hansen ES, Pinborg LH, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neurcpsychopharmacol 2005; 8: 391-401.
79. Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65(suppl 14): 11-17.
80. van der Wee NJ, Stevens H, Hardeman JA, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]beta-CIT SPECT. Am J Psychiatry 2004; 161: 2201-2206.
81. Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 1998; 112: 1475-1485.
82. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69-81.
83. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000; 877: 23-30.
84. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424-428.
85. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction-newer targets for anti-obsessional drugs. Recent Patents CNS Drug Discov 2007; 2: 47-55.
86. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23: 1-5.
87. Rubio G, Jimenez-Arriero MA, Martinez-Gras I, et al. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006; 26: 341-344.
88. Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006; 21: 189-191.
89. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003; 167: 219-220.
90. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006; 184: 254-256.
91. Berlin HA, Koran L, Jenike M, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder in preperation for neuropsychopharmacology.
92. Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 358-363.
93. Inouye E. Similar and dissimilar manifestations of obsessive-compulsive neuroses in monozygotic twins. Am J Psychiatry 1965; 121: 1171-1175.
94. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158: 1568-1578.
95. Carey G II. Twin and family studies of anxiety, phobic and obsessive disorders. In: Klein DF, Rabkin JG, eds. Anxiety: New Research and Challenging Concepts. New York, NY: Raven Press; 1981; 117-136.
96. Clifford CA, Murray RM, Fulker DW. Genetic and environmental influences on obsessional traits and symptoms. Psychol Med 1984; 14: 791-800.
97. Jonnal AH, Gardner CO, Prescott CA, et al. Obsessive and compulsive symptoms in a general population sample of female twins. Am J Med Genet 2000; 96: 791-796.
98. Pauls DL, Alsobrook JP II, Goodman W, et al. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 76-84.
99. Bellodi L, Sciuto G, Diaferia G, et al. Psychiatric disorders in the families of patients with obsessive-compulsive disorder. Psychiatry Res 1992; 42: 111-120.
100. do Rosario-Campos MC, Leckman JF, Curi M, et al. A family study of early-onset obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2005; 136: 92-97.
101. Hanna GL, Himle JA, Curtis GC, et al. A family study of obsessive-compulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 13-19.
102. Alsobrook IJ, Leckman JF, Goodman WK, et al. Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am J Med Genet 1999; 88: 669-675.
103. Pauls DL, Alsobrook JP II. The inheritance of obsessive-compulsive disorder. Child Adolesc Psychiatr Clin N Am 1999; 8: 481-496.
104. Hanna GL, Veenstra-VanderWeele J, Cox NJ, et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet 2002; 114: 541-552.
105. Shugart YY, Samuels J, Willour VL, et al. Genome-wide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Mol Psychiatry 2006; 11: 763-770.
106. Pitman RK, Green RC, Jenike MA, et al. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 1166-1171.
107. Leonard HL, Lenane MC, Swedo SE, et al. Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry 1992; 149: 1244-1251.
108. Rapoport JL, Inoff-Germain G. Treatment of obsessive-compulsive disorder in children and adolescents. J Child Psychol Psychiatry 2000; 41: 419-431.
109. Grados MA, Riddle MA, Samuels JF, et al. The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: the Hopkins OCD family study. Biol Psychiatry 2001; 50: 559-565.
110. Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. N Engl J Med 1986; 315: 993-997.
111. Walkup JT, LaBuda MC, Singer HS, et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59: 684-693.
112. Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery 2007; 61: 1-11; discussion 11-13.
113. Willour VL, Yao Shugart Y, Samuels J, et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet 2004; 75: 508-513.
114. Veenstra-VanderWeele J, Kim SJ, Gonen D, et al. Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder. Mol Psychiatry 2001; 6: 160-167.
115. Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004; 174: 530-538.
116. Chabane N, Millet B, Delorme R, et al. Lack of evidence for association between serotonin transporter gene (5-HTTLPR) and obsessive-compulsive disorder by case control and family association study in humans. Neurosci Lett 2004; 363: 154-156.
117. Hall D, Dhilla A, Charalambous A, et al. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet 2003; 73: 370-376.
118. Millet B, Chabane N, Delorme R, et al. Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2003; 116: 55-59.
119. Mundo E, Richter MA, Zai G, et al. 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol Psychiatry 2002; 7: 805-809.
120. Zai G, Bezchlibnyk YB, Richter MA, et al. Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2004; 129: 64-68.
121. Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003; 8: 933-936.
122. Billett EA, Richter MA, Sam F, et al. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr Genet 1998; 8: 163-169.
123. Baxter LR, Clark EC, Iqbal M, et al. Cortical-subcortical systems in the mediation of obsessive-compulsive disorder. In: Lichter DG, Cummings JL, eds. Frontal-Subcortical Circuits in Psychiatric and Neurological Disorders. New York, NY: Guilford Press; 2000; 207-230.
124. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769-776.
125. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 778-785.
126. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3- mutant mice. Nature 2007; 448: 894-900.
127. Hemmings SM, Stein DJ. The current status of association studies in obsessive-compulsive disorder. Psychiatr Clin N Am 2006; 29: 411-444.
128. Gothelf D, Aharonovsky O, Horesh N, et al. Life events and personality factors in children and adolescents with obsessive-compulsive disorder and other anxiety disorders. Compr Psychiatry 2004; 45: 192-198.
129. Khanna S, Rajendra PN, Channabasavanna SM. Life events and onset of obsessive compulsive disorder. Int J Soc Psychiatry 1988; 34: 305-309.
130. de Silva P, Marks M. The role of traumatic experiences in the genesis of obsessive-compulsive disorder. Bebav Res Ther 1999; 37: 941-951.
131. Lochner C, du Toit PL, Zungu-Dirwayi N, et al. Childhood trauma in obsessive-compulsive disorder, trichotillomania, and controls. Depress Anxiety 2002; 15: 66-68.
132. Neziroglu F, Anemone R, Yaryura-Tobias JA. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992; 149: 947-950.
133. Sichel DA, Cohen IS, Dimmock JA, et al. Postpartum obsessive compulsive disorder: a case series. J Clin Psychiatry 1993; 54: 156-159.
134. Maina G, Albert U, Bogetto F, et al. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999; 89: 49-58.
135. Lochner C, Hemmings SM, Kinnear CJ, et al. Gender in obsessive-compulsive disorder: clinical and genetic findings. Eur Neuropsychopharmacol 2004; 14: 105-113.
136. Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry 1997; 58: 330-334; quiz 335-336.
137. Giulino, L, Gammon P, Sullivan K, et al. Is parental report of upper respiratory infection at the onset of obsessive-compulsive disorder suggestive of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection? J Child Adolesc Psychcpharmacol 2002; 12: 157-164.
138. Murphy TK, Sajid M, Soto O, et al. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol Psychiatry 2004; 55: 61-68.
139. Snider LA, Swedo SE. Childhood-onset obsessive-compulsive disorder and tic disorders: case report and literature review. J Child Adolesc Psychopharmacol 2003; 13(suppl 1): S81-S88.
140. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics 2005; 116: 56-60.
141. Dale RC, Heyman I. Post-streptococcal autoimmune psychiatric and movement disorders in children. Br J Psychiatry 2002; 181: 188-190.
142. Dale RC, Heyman I, Giovannoni G, et al. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. Br J Psychiatry 2005; 187: 314-319.
143. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155: 264-271.
144. Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup separating fact from fiction. Pediatrics 2004; 113: 907-911.
145. Luo F, Leckman JF, Katsovich L, et al. Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly acquired streptococcal infections. Pediatrics 2004; 113(1): e578-585.
146. Clark DA. Cognitive-Behavioral Therapy for OCD. New York, NY: Guilford Press; 2004.
147. Rachman S. A cognitive theory of obsessions. Bebav Res Ther 1997; 35: 793-802.
148. Salkovskis PM, Richards C, Forrester E. The relationship between obsessional problems and intrusive thoughts. Behav Cogn Psychother 1995; 23: 281-299.
149. Wells A. Emotional Disorders and Metacognition: Innovative Cognitive Therapy. New York, NY: John Wiley & Sons; 2000.
150. Berle D, Starcevic V. Thought-action fusion: review of the literature and future directions. Clin Psychol Rev 2005; 25: 263-284.
151. Frost R, Steketee G. Cognitive Approacbes to Obsessions and Compulsions Theory, Assessment, and Treatment; Amsterdam, The Netherlands: Pergamon/Elsevier Science; 2002.
152. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 374-388.
153. Korff S, Harvey BH. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin N Am 2006; 29: 371-390.
154. Powell SB, Newman HA, Pendergast JF, et al. A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 1999; 66: 355-363.
155. Presti MF, Lewis MH. Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior. Bebav Brain Res 2005; 157: 363-368.
156. Woods A, Smith C, Szewczak M, et al. Selective serotonin re-uptake inhibitors decrease schedule- induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl) 1993; 112: 195-198.
157. Altemus M, Glowa JR, Galliven E, et al. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav 1996; 53: 123-131.
158. Broekkamp CL, Jenck F. The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs. In: Bevan P, Cools R, Archer T, eds. Bebavioural Pharmacology of 5-HT. Hillsdale, NJ: Erlbaum; 1989; 321-335.
159. Broekkamp CL, Rijk HW, Joly-Gelouin D, et al. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 1986; 126: 223-229.
160. Gyertyan I. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 1995; 6: 24-31.
161. Londei T, Valentini AM, Leone VG. Investigative burying by laboratory mice may involve non-functional, compulsive behaviour. Bebav Brain Res 1998; 94: 249-254.
162. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991; 38: 63-67.
163. Szechtman H, Woody E. Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev 2004; 111: 111-127.
164. Otto MW. Normal and abnormal information processing. A neuropsychological perspective on obsessive compulsive disorder. Psychiatr Clin N Am 1992; 15: 825-848.
165. Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003; 28: 77-85.
166. Joel D, Ben-Amir E, Doljansky J, et al. 'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behav Pharmacol 2004; 15: 241-252.
167. Brimberg L, Flaisher-Grinberg S, Schilman EA, et al. Strain differences in 'compulsive' lever-pressing. Behav Brain Res 2007; 179: 141-151.
168. Campbell KM, de Lecea L, Severynse DM, et al. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 1999; 19: 5044-5053.
169. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 2002; 7: 617-625, 524.
170. Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in mice. Neuron 2002; 33: 23-34.
171. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998; 4: 1152-1156.
172. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546.
173. Vickers SP, Clifton PG, Dourish CT, et al. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 1999; 143: 309-314.
174. Chou-Green JM, Holscher TD, Dallman MF, et al. Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol Behav 2003; 78: 641-649.
175. Berridge KC, Aldridge JW, Houchard KR, et al. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol 2005; 3: 4.
176. Yadin E, Friedman E, Bridger WH. Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 1991; 40: 311-315.
177. Eilam D, Szechtman H. Towards an animal model of obsessive-compulsive disorder (OCD): sensitization to dopamine agonist quinpirole. Soc Neurosci Abstr 1995; 21: 192.
178. Szechtman H, Eckert MJ, Tse WS, et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2001; 2: 4.
179. Ben-Pazi A, Szechtman H, Eilam D. The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci 2001; 115: 1301-1317.
180. Zadicario P, Ronen S, Eilam D. Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. BMC Neurosci 2007; 8: 23.
181. Meyer V. Modification of expectations in cases with obsessional rituals. Bebav Res Ther 1966; 4: 273-280.
182. Steketee G. Behavioural assessment and treatment planning with obsessive compulsive disorder: a review emphasizing clinical application. Bebav Ther 1994; 25: 613-633.
183. Beck AT. Cognitive Therapy and the Emotional Disorders. New York, NY: International Universities Press; 1976.
184. Salkovskis PM. Obsessional-compulsive problems: a cognitive-behavioural analysis. Behav Res Ther 1985; 23; 571-583.
185. Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2007:; CD005333.
186. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995; 166: 424-443.
187. Ellingrod VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy 1998; 18: 936-960.
188. Soomro G, Oakley-Browne M, Doughty C. Serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorders (OCD). Cochrane Database Syst Rev 2006:; CD001765.
189. March JS, Frances A, Carpenter D, et al. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 4): 13-72.
190. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47: 411-418.
191. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, et al. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998; 97: 374-380.
192. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 309-317.
193. Kulz AK, Meinzer S, Kopasz M, et al. Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology 2007; 56: 127-131.
194. Smeraldi E, Diaferia G, Erzegovesi S, et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996; 40: 398-402.
195. Huwig-Poppe C, Voderholzer U, Backhaus J, et al. The tryptophan depletion test. Impact on sleep in healthy subjects and patients with obsessive-compulsive disorder. Adv Exp Med Biol 1999; 467: 35-42.
196. Berney A, Sookman D, Leyton M, et al. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry 2006; 59: 853-857.
197. Marks IM, Stem RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals: i. Br J Psychiatry 1980; 136: 1-25.
198. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152: 522-534.
199. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5: 17-30.
200. Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998;; 71-78.
201. van Balkom AJ, de Haan E, van Oppen P, et al. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998; 186: 492-499.
202. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 151-161.
203. Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292: 1969-1976.
204. Tenneij NH, van Megen HJ, Denys DA, et al. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 2005; 66: 1169-1175.
205. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 2004; 19: 225-233.
206. Baxter LR Jr, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681-689.
207. Schwartz JM, Stoessel PW, Baxter LR Jr, et al. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 109-113.
208. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46: 36-44.
209. McDonough M, Kennedy N. Pharmacological management of obsessive-compulsive disorder: a review for clinicians. Harvard Rev Psychiatry 2002; 10: 127-137.
210. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002; 63(suppl 6): 20-29.
211. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993; 54(suppl 6): 16-26.
212. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191.
213. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003; 54: 1111-1118.
214. Alacron RD, Libb JW, Spitler D. A predictive study of obsessive compulsive response to clomipramine. J Clin Psychopharmacol 1993; 13: 210-213.
215. Erzegovesi S, Cavellini MC, Cavedini P, et al. Clinical predictors of drug response in obsessive compulsive disorder. J Clin Psychopharmacol 2001; 21: 272-275.
216. Ravizza. L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 368-373.
217. Wheadon DE, Bushnell WD, Steiner M. A fixed-dose comparison of 20, 40 or 60 mg paroxetine or placebo in the treatment of obsessive-compulsive disorder. Paper presented at: 32nd Annual Meeting of the American College of Neuropsychopharmacology; December 13-17, 1993; Honolulu, Hawaii.
218. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), part I: development, use and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
219. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry 1989; 46: 1012-1016.
220. Diering SL, Bell WO. Functional neurosurgery for psychiatric disorders: a historical perspective. Stereotact Funct Neurosurg 1991; 57: 175-194.
221. Mashour GA, Walker EE, Marruza RL. Psychosurgery: past, present, and future. Brain Res Rev 2005; 48: 409-419.
222. Hollander E, Stein DJ, Kwon JH, et al. Psychosocial. function and economic costs of obsessive-compulsive disorder. CNS Spectr 1997; 2: 16-25.
223. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am 2000; 23: 509-517.
224. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive compulsive disorder. Int J Neuropsychopharmacol 2004; 7: 1-23.
225. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 423-429.
226. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 1990; 147: 652-654.
227. McDougle CJ, Fleishmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56(suppl 11): 526-528.
228. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive compulsive disorder. J Clin Psychiatry 1997; 58(suppl 3): 119-122.
229. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-184.
230. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11-18.
231. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-308.
232. Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive compulsive disorder: a crossover study.J Clin Psychiatry 2005; 66: 736-743.
233. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801.
234. Hollander E, Baldini RN, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003; 6: 397-401.
235. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005; 15: 69-74.
236. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-568.
237. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo controlled trial of olanzapine addition in fluoxetine refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55: 553-555.
238. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1040-1048.
239. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN830507621. BMC Psychiatry 2005; 5: 5.
240. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive compulsive disorder. a randomized controlled treatment study. Int Clin Psychopharmacol 2005; 20: 223-226.
241. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115-119.
242. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-632.
243. Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 2003; 18: 23-28.
244. Joffe RT, Swinson RP. Carbamazepine in obsessive compulsive disorder. Biol Psychiatry 1987; 22: 1169-1171.
245. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59: 480-481.
246. Sporn. J, Smith M, Jersino JM, et al. A double-blind, placebo-controlled trial of gabapentin (GBP) augmentation of fluoxetine for treatment of obsessive-compulsive disorder (OCD). Poster presented at: New Clinical Drug Evaluation Unit Program; May 28-31, 2001; Phoenix, AZ.
247. van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open label case series. Depress Anxiety 2006; 23: 1-5.
248. George MS. New methods of brain stimulation are improving research and therapy in obsessive-compulsive disorder. CNS Spectr 2000; 5(suppl 4): 12-17.
249. Jenike MA, Rauch SL, Baer L, Rasmussen SA. Neurosurgical treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Practical Management. St Louis, MO: Mosby; 1998; 592-610.
250. Freeman C, Crossley D, Eccleston D. Neurosurgery for Mental Disorder: Report from the Neurosurgery Working Group of the Royal College of Psychiatrists. London, United Kingdom: Royal College of Psychiatrists; 2000; CR89.
251. Greenberg BD, Price LH, Rauch SL, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am 2003; 14: 199-212.
252. Lisanby SH, ed. Brain Stimulation in Psychiatric Treatment. Arlington, VA: American Psychiatric Publishing; 2004.
253. American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging. A Task Force Report of the American Psychiatric Association. 2nd ed. Washington, DC: American Psychiatric Association; 2001.
254. Maletzky B, McFarland B, Burt A. Refractory obsessive compulsive disorder and ECT. Convuls Ther 1994; 10: 34-42.
255. Khanna S, Gangadhar BN, Sinha V, et al. Electroconvulsive therapy in obsessive-compulsive disorder. Convuls Ther 1988; 4: 314-320.
256. Mellman LA, Gorman JM. Successful treatment of obsessive-compulsive disorder with ECT. Am J Psychiatry 1984; 141: 596-597.
257. Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 1899-1900.
258. Casey DA, Davis MH. Obsessive-compulsive disorder responsive to electroconvulsive therapy in an elderly woman. South Med J 1994; 87: 862-864.
259. Lavin MR, Halligan P. ECT for comorbid obsessive compulsive disorder and schizophrenia. Am J Psychiatry 1996; 153: 1652-1653.
260. Thomas SG, Kellner CH. Remission of major depression and obsessive-compulsive disorder after a single unilateral ECT. J ECT 2003; 19: 50-51.
261. Strassnig M, Riedel M, Muller N. Electroconvulsive therapy in a patient with Tourette's syndrome and comorbid obsessive compulsive disorder. World J Biol Psychiatry 2004; 5: 164-166.
262. Beale MD, Kellner CH, Pritchett JT, et al. ECT for OCD. J Clin Psychiatry 1995; 56: 81-82.
263. Chung MS, Huang SC, Tsai SJ, et al. Mania associated with electroconvulsive therapy in a patient with obsessive compulsive disorder. Int Med J 2001; 8: 185-186.
264. Rapoport M, Feder V, Sandor P. Response of major depression and Tourette's syndrome to ECT: a case report. Psychosom Med 1998; 60: 528-529.
265. Husain SS, Kevan IM, Linnell R, et al. Electroconvulsive therapy in depressive illness that has not responded to drug treatment. J Affect Disord 2004; 83: 121-126.
266. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005; CD000076.
267. National Institute for Health and Clinical Excellence. Guidance on the Use of Electroconvulsive Therapy. Technology Appraisal 59. London, United Kingdom: National Institute for Health and Clinical Excellence; 2003.
268. Sackeim HA. Magnetic stimulation therapy and ECT. Convuls Ther 1994; 10: 255-258.
269. Lisanby SH. Update on magnetic seizure therapy (MST): a novel form of convulsive therapy. J ECT 2002; 18: 182-188.
270. Dell'Osso B, Altamura AC, Allen A, Hollander E. Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr 2005; 10: 966-979, 983.
271. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985; 1: 1106-1107.
272. Bickford RG, Guidi M, Fortesque P, et al. Magnetic stimulation of human peripheral nerve and brain: response enhancement by combined magnetoelectrical technique. Neurosurgery 1987; 20: 110-116.
273. George MS, Lisanby SH, Sackeim HA, et al. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry 1999; 56: 300-311.
274. Pascual-Leone A, Valls-Sole J, Wasserman EM, et al. Responses to rapid rate transcranial magnetic stimulation of the human motor cortex. Brain 1994; 117: 847-858.
275. Pascual-Leone A, Catala MD, Pascual-Leone PA. Lateralized effect of rapid-rate transcranial magnetic stimulation of the prefrontal cortex on mood. Neurology 1996; 46: 499-502.
276. Chen R, Classen J, Gerloff C, et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997; 48: 1398-1403.
277. Bohning DE, Shastry A, Wassermann EM, et al. BOLD-fMRI response to single-pulse transcranial magnetic stimulation (TMS). J Magn Reson Imaging 2000; 11(569): 574.
278. Catafau A, Perez V, Gironell A, et al. SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients: a pilot study. Psychiatry Res 2001; 106: 151-160.
279. Schaepfer TE, Kosel M. Transcranial magnetic stimulation in depression. In: Lisanby SH, ed. Brain Stimulation in Psychiatric Treatment. Arlington, VA: American Psychiatric Publishing; 2004; 1-22.
280. Martin JL, Barbanoj MJ, Perez V, et al. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev 2003; CD003387.
281. Bohning DE, Pecheny AP, Epstein CM, et al. Mapping transcranial magnetic stimulation (TMS) in vivo with MRI. Neuroreport 1997; 8: 2535-2538.
282. Paus T, Jech R, Thompson J, et al. Transcranial magnetic stimulation during positron emission tomography: a new method for studying connectivity of the human cerebral cortex. J Neurosci 1997; 17: 3178-3184.
283. George MS, Nahas Z, Kozel A, et al. Mechanisms and the current state of transcranial magnetic stimulation. CNS Spectr 2003; 496-502, 511-514.
284. Roth Y, Zangen A, Hallett M. A coil design for transcranial magnetic stimulation of deep brain regions. J Clin Neurophysiol 2002; 19: 361-370.
285. Ferrao YA, Shavitt RG, Bedin NR, et al. Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord 2006; 94: 199-209.
286. Lopes AC, de Mathis ME, Canteras MM, et al. Update on neurosurgical treatment for obsessive compulsive disorder. Rev Bras Psiquiatr 2004; 26: 62-66.
287. Schruers K, Koning K, Luermans J, et al. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 2005; 111: 261-271.
288. Kiloh LG, Smith JS, Johnston GF. Psychosurgery (limbic surgery). In: Kiloh LG, Smith JS, Johnston GF eds. Physical Treatments in Psychiatry. Melbourne, Australia: Blackwell; 1988; 277-333.
289. Waziri, R. Psychosurgery for anxiety and obsessive-compulsive disorders. In: Noyes R, Roth M, Burrows GD, eds. The Treatment of Anxiety: Handbook of Anxiety. Amsterdam, The Netherlands: Elsevier; 1990.
290. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ. Translational principles of deep brain stimulation. Nat Rev Neurosci 2007; 8: 623-635.
291. Rezai AR, Mogilner AY, Cappell J, et al. Integration of functional brain mapping in image-guided neurosurgery. Acta Neurochir Suppl 1997; 68: 85-89.
292. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000; 342: 461-468.
293. Schruers K, Koning K, Luermans J, et al. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 2005; 111: 261-271.
294. Lozano AM, Dostrovsky J, Chen R, Ashby P. Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol 2002; 1: 225-231.
295. McIntyre CC, Savasta M, Walter BL, Vitek JL. How does deep brain stimulation work? Present understanding and future questions. J Clin Neurophysiol 2004; 21: 40-50.
296. Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord 2002; 17(suppl 3): S63-S68.
297. Benabid, AL, Pollak P, Gervason C, et al. Long term suppression of tremor by chronic stimulation of ventral intermediate thalamic nucleus. Lancet 1991; 337: 402-406.
298. Blond S, Caparros-Lefebvre D, Parker F, et al. Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. J Neurosurg 1992; 77: 62-68.
299. Tass PA, Klosterkotter J, Schneider F, et al. Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting. Neuropsychopharmacology 2003; 28(suppl 1): S27-S34.
300. Greenberg BD. Deep brain stimulation in psychiatry. In: Lisanby SH, ed. Brain Stimulation in Psychiatric Treatment. Arlington, VA: American Psychiatric Publishing; 2004; 53-65.
301. Boraud T, Bezard E, Bioulac B, Gross C. High frequency stimulation of the internal globus pallidus (GPi) simultaneously improves Parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey. Neurosci Lett 1996; 215: 17-20.
302. Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. Neurology 2000; 55(suppl 6): S13-S16.
303. Hashimoto T, Elder CM, Okun MS, et al. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J Neurosci 2003; 23: 1916-1923.
304. Devos S, Labyt E, Derambure P, et al. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease. Brain 2004; 127: 408-419.
305. Hamani C, Lozano AM. Physiology and pathophysiology of Parkinson's disease. Ann N Y Acad Sci 2003; 991: 15-21.
306. Hamani C, Richter E, Schwalb JM, Lozano AM. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery 2005; 56: 1313-1324.
307. Hamani C, Neimat J, Lozano AM. Deep brain stimulation for the treatment of Parkinson's disease. J Neural Transm Suppl 2006; 70: 393-399.
308. Lozano AM, Mahant N. Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat Disord 2004; 10(suppl 1): S49-S57.
309. Deuschl G, Bain P. Deep brain stimulation for tremor [correction of trauma]: patient selection and evaluation. Mov Disord 2002; 17(S3): 102-111.
310. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol 1998; 49: 145-153.
311. Pollak P, Fraix V, Krack P, et al. Treatment results: Parkinson's disease. Mov Disord 2002; 17(suppl 3): 75-83.
312. Rauch SL, Dougherty DD, Malone D, et al. A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder. J Neurosurg 2006; 104: 558-565.
313. Nuttin B, Cosyns P, Demeulemeester H, et al. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 1999; 354: 1526.
314. Nuttin BJ, Gabriels L, van Kuyck K, et al. Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive compulsive disorder: anecdotal reports. Neurosurg Clin N Am 2003; 14: 267-274.
315. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003; 52: 1263-1272.
316. Gabriels L, Cosyns P, Nuttin B, et al. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003; 107: 275-282.
317. de la Fuente-Fernández R. Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 125-127.
318. Sturm V, Lenartz D, Koulousakis A, et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat 2003; 26: 293-299.
319. Shumyatsky GP, Tsvetkov E, Malleret G, et al. Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear. Cell 2002; 111: 905-918.
320. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Trans Gen 1993; 9: 111-134.
321. Mulder AB, Hodenpijl MG, Lopes da Silva FH. Electrophysiology of the hippocampal and amygdaloid projections to the nucleus accumbens of the rat: convergence, segregation, and interaction of inputs. J Neurosci 1998; 18: 5059-5102.
322. Rosenkranz JA, Grace AA. Modulation of basolateral amygdale neuronal firing and afferent drive by dopamine receptor activation in vivo. J Neurosci 1999; 15: 11027-11039.
323. Abelson JL, Curtis GC, Sagher O, et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005; 57: 510-516.
324. Greenberg BD, Malone DA, Friehs GM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31: 2384-2393.
325. Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation. Case report. J Neurosurg 2003; 98: 1104-1108.
326. Fontaine D, Mattei V, Borg M, et al. Effect of subthalamic nucleus stimulation on obsessivecompulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg 2004; 100: 1084-1086.
327. Mallet L, Mesnage V, Houeto JL, et al. Compulsions, Parkinson's disease, and stimulation. Lancet 2002; 360: 1302-1304.
328. Aouizerate B, Cuny E, Martin-Guehl C, et al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004; 101: 682-686.
329. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651-660.
330. Greenberg BD, Nahas Z, Carpenter LL. Current status of deep brain stimulation. Prim Psychiatry 2005; 12: 59-64.
331. Alterman RL, Miravite J, Weisz D, et al. Sixty hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007; 69: 681-688.
332. Koran LM, Quirk T, Lorberbaum JP, Elliott M. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 2001; 21: 537-539.
333. Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005; 66: 515-520.
334. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997; 154: 1261-1264.
335. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 219-224.
336. Koran LM, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? J Clin Psychopharmacol 1996; 16: 253-254.
337. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 1025-1030.
338. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 1997; 7: 147-155.
339. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999; 2: 193-195.
340. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983; 80: 231-235.
341. Shapira NA, Keck PE Jr, Goldsmith TD, et al. Openlabel pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997; 6: 170-173.
342. Rauch S. Neuroimaging research and the neurobiology of obsessive-compulsive disorder: where do we go from here? Biol Psychiatry 2000; 47: 168-170.
343. Finn DA, Rutledge-Gorman MT, Crabbe JC. Genetic animal models of anxiety. Neurogenetics 2003; 4: 109-135.
344. Grados M, Wilcox HC. Genetics of obsessive-compulsive disorder: a research update. Expert Rev Neurother 2007; 7: 967-980.
345. Leckman JF, Zhang H, Alsobrook JP, Pauls DL. Symptom dimensions in obsessive-compulsive disorder: toward quantitative phenotypes. Am J Med Genet 2001; 105: 28-30.
346. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet 2004; 75: 353-362.
347. Tsaltas E, Kontis D, Chrysikakou S, et al. Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2D and 5-HT1D receptor involvement in OCD pathophysiology. Biol Psychiatry 2005; 57: 1176-1185.
348. Joel D, Avisar A. Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder? Behav Brain Res 2001; 123: 77-87.
349. Savage CR, Keuthen NJ, Jenike MA. Recall and recognition memory in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1996; 8: 99-103.
350. Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000; 47: 296-304.
351. Greenberg BD, George MS, Martin JD, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry 1997; 154: 867-869.
352. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind placebo-controlled study. Am J Psychiatry 2001; 158: 1143-1145.
353. Sachdev PS, McBride R, Loo CK, et al. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry 2001; 62: 981-984.
354. Mantovani A, Lisanby SH, Pieraccini F, et al. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 2006; 9: 95-100.
355. Strom-Olsen R, Carlisle S. Bi-frontal stereotactic tractotomy: a follow-up study of its effects on 210 patients. Br J Psychiatry 1971; 118: 141-154.
356. Goktepe EO, Young LB, Bridges PK. A further review of the results of stereotactic subcaudate tractotomy. Br J Psychiatry 1975; 126: 270-280.
357. Woerdeman PA, Willems PW, Noordmans HJ, et al. Frameless stereotactic subcaudate tractotomy for intractable obsessive-compulsive disorder. Acta Neurochir (Wien) 2006; 148: 633-637.
358. Leksell L. A stereotaxic apparatus for intracerebral surgery. Acta Chir Scand 1949; 99: 229-233.
359. Herner T. Treatment of mental disorders with frontal stereotactic thermo-lesions: a follow-up of 116 cases. Acta Psychiatr Scand Suppl 1961; 36.
360. Bingley T, Leksell L, Meyerson BA, et al. Long term results of stereotactic capsulotomy in chronic obsessive-compulsive neurosis. In: Sweet WH, Borador Alcalde S, Martin-Rodriguez JG, eds. Neurosurgical Treatment in Psychiatry, Pain, and Epilepsy: Proceedings of the Fourth World Congress of Psychiatric Surgery, September 7-10, 1975, Madrid, Spain. Baltimore, MD: University Park Press; 1977; 287.
361. Fodstad H, Strandman E, Karlsson B, et al. Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. Acta Neurochir (Wien) 1982; 62: 1-23.
362. Guo WY, Lindquist C, Kihlström P, et al. Radionecrosis Created in the Internal Capsule for Psychosurgery with the Gamma Knife [dissertation]. Stockholm, Sweden: Karolinska Institut; 1993.
363. Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J Neuropsychiatry Clin Neurosci 1994; 6: 467-477.
364. Lippitz BE, Mindus P, Meyerson BA, et al. Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere. Neurosurgery 1999; 44: 452-460.
365. Christensen DD, Laitinen LV, Schmidt LJ, et al. Anterior capsulotomy for treatment of refractory obsessive-compulsive disorder: results in a young and an old patient. Stereotact Funct Neurosurg 2002; 79: 234-244.
366. Oliver B, Gascon J, Aparicio A, et al. Bilateral anterior capsulotomy for refractory obsessive-compulsive disorders. Stereotact Funct Neurosurg 2003; 81: 90-95.
367. Tippin J, Henn FA. Modified leukotomy in the treatment of intractable obsessional neurosis. Am J Psychiatry 1982; 139: 1601-1603.
368. Jenike MA, Baer L, Ballantine T, et al. Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch Gen Psychiatry 1991; 48: 548-555.
369. Baer L, Rauch SL, Ballantine HT Jr, et al. Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 1995; 52: 384-392.
370. Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 2002; 159: 269-275.
371. Spangler WJ, Cosgrove GR, Ballantine HT, et al. Magnetic resonance image-guided stereotactic cingulotomy for intractable psychiatric disease. Neurosurgery 1996; 38: 1071-1076.
372. Kim CH, Chang JW, Koo MS, et al. Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand 2003; 107: 283-290.
373. Richter EO, Davis KD, Hamani C, et al. Cingulotomy for psychiatric disease: microelectrode guidance, a callosal reference system for documenting lesion location, and clinical results. Neurosurgery 2004; 54: 622-628.
374. Jung HH, Kim CH, Chang JH, et al. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: long-term follow-up results. Stereotact Funct Neurosurg 2006; 84: 184-189.
375. Cumming S, Hay P, Lee T, et al. Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder. Aust N Z J Psychiatry 1995; 29: 293-298.
376. Hay P, Sachdev P, Cumming S, et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 1993; 87: 197-207.
377. Sachdev P, Hay P. Does neurosurgery for obsessive-compulsive disorder produce personality change? J Nerv Ment Dis 1995; 183: 408-413.
378. Sachdev P. Site and size of lesion and psychosurgical outcome in obsessive compulsive disorder: a magnetic resonance imaging study. Biol Psychiatry 1996; 39: 739-742.
379. Irle E, Exner C, Thielen K, et al. Obsessive-compulsive disorder and ventromedial frontal lesions: clinical and neuropsychological findings. Am J Psychiatry 1998; 155: 255-263.
380. Sachdev P, Trollor J, Walker A, et al. Bilateral orbitomedial leucotomy for obsessive-compulsive disorder: a single-case study using positron emission tomography. Aust N Z J Psychiatry 2001; 35: 684-690.
381. Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery 2002; 50: 1043-1052.